Authors


Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA

Latest:

Dr. McBride on the Potential of Biosimilars in Oncology

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.


Ali McBride, PharmD, MS, BCPS

Latest:

Dr. McBride on the Excitement With Oral Oncolytics

Ali McBride, PharmD, MS, BCPS, clinical coordinator, Hematology/Oncology, secretary, Association of Community Cancer Centers (ACCC), discusses the importance with and excitement of oral oncolytics.


Ali Sadoughi, MD

Latest:

"Ultrathin" Bronchoscopy Improves Care for Patients With Lung Nodules

To spare patients from surgery or other unnecessary procedures, Montefiore Einstein Center for Cancer Care developed an advanced method of bronchoscopy that provides peace of mind for individuals with lung nodules. The minimally invasive bronchoscopy provides a very safe method of biopsy, importantly at very early stages when the nodules are relatively small.



Alice Goodman

Latest:

Small Renal Masses in Elderly Can Be Managed by Surveillance

Small renal masses identified in elderly patients can be safely managed by surveillance and maintain the same mortality risk as those who undergo surgery, suggesting that surgery could be avoided altogether in many patients.


Alice Mims, MD

Latest:

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).


Alice S. Mims, MD

Latest:

Dr. Mims on the Beat AML Master Trial in AML

Alice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).



Alice T. Shaw, MD, PhD

Latest:

Dr. Shaw on Sequencing Strategies in ALK-Positive NSCLC

Alice T. Shaw, MD, PhD, associate professor of medicine at Harvard Medical School, director of Thoracic Oncology and Paula O’Keefe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, discusses sequencing strategies in ALK-positive non–small cell lung cancer (NSCLC).



Alice Ulhoa-Cintra, MD

Latest:

Using QOPI to Improve Quality Within Your Fellowship Program

The QOPI program creates a uniform measurement of the quality of care delivered by an oncologist; this affords self-examination and directed improvement of practices.


Alice Y. Ho, MD

Latest:

Dr. Ho on Postmastectomy Radiation Therapy

Alice Y. Ho, MD, discusses postmastectomy radiation therapy for patients with breast cancer who have undergone breastreconstructive surgery.




Alicia Latham Schwark, MD

Latest:

Dr. Schwark on Microsatellite Instability and Lynch Syndrome

Alicia Latham Schwark, MD, medical genetics fellow, Memorial Sloan Kettering Cancer Center, discusses a study exploring microsatellite instability (MSI) and how it relates to Lynch syndrome across all tumor types. The findings were presented at the 2018 ASCO Annual Meeting.


Alicia Morgan, MD

Latest:

Dr. Morgans on the Current Treatment Landscape For mHSPC

Alicia Morgans, MD, MPH, discusses current androgen deprivation therapy combinations and the investigation of radiopharmaceutical combinations for metastatic hormone-sensitive prostate cancer.




Alison J. Moskowitz, MD

Latest:

Dr. Moskowitz on the Challenges of Intensifying Treatment in Hodgkin Lymphoma

Alison J. Moskowitz, MD, discusses the challenges of intensifying treatment in Hodgkin lymphoma.


Alison R. Sehgal, MD

Latest:

Dr. Sehgal on Key Targetable Alterations in AML

Alison R. Sehgal, MD, discusses key targetable alterations in acute myeloid leukemia.


Alison Rager Sehgal, MD

Latest:

Dr. Sehgal on the Structure and Manufacturing Process of CAR T Cells

Alison Rager Sehgal, MD, assistant professor of medicine, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the structure and manufacturing process of CAR T cells.


Alison Stopeck, MD, Rowan T. Chlebowski, MD, PhD

Latest:

SABCS Interview Series

The January issue of OBTN featured highlights from the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). We wrap up our SABCS coverage this month with interviews on denosumab with Alison Stopeck, MD, associate professor of medicine at the University of Arizona and director of the Clinical Breast Cancer Program at the Arizona Cancer Center; oral bisphosphonates with Rowan T.Chlebowski, MD, PhD, professor and chief of the Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center; and adjuvant chemotherapy�induced alopecia with Hugues Bourgeois, MD, Centre Jean Bernard in Lemans, France.


Allen L. Cohn, MD

Latest:

Dr. Cohn on Frontline Therapies in Metastatic Pancreatic Cancer

Allen L. Cohn, MD, medical oncologist, Rocky Mountain Cancer Centers, discusses frontline therapies in metastatic pancreatic cancer.


Allen S. Lichter, MD

Latest:

Dr. Lichter on the Importance of the UN Summit on NCDs

Dr. Allen S. Lichter the chief executive officer of ASCO on the Importance of the UN Summit on NCD


Allie Casey

Latest:

Affordable Care Act Positively Affects Stage at Diagnosis

More Stage I cancers were diagnosed after the passage of the Affordable Care Act within five screenable disease types than were diagnosed before ACA implementation.


Allie Strickler

Latest:

AR Emerges as a Potential Target in Triple-Negative Breast Cancer

Whereas the androgen receptor (AR) is a common target in prostate cancer, emerging findings are showing a potential role for targeting AR in breast cancer, as well.


Allison Betof Warner, MD, PhD

Latest:

Dr. Warner Discusses Findings from COMBI-i Trial in Melanoma

Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.


Allison C. Rosenthal, DO

Latest:

Dr. Rosenthal on FDA Approval of Ibrutinib in Marginal Zone Lymphoma

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).


Allison Inserro

Latest:

Oncology Payment Models Fall Short of Desired Goals

There is a year and a half remaining in the life of the Oncology Care Model, and although the Centers for Medicare & Medicaid Services has leapt forward with a vision for the next-generation model of care Oncology Care First, many stakeholders feel that the Oncology Care Model is more than enough to think about right now.


Allison Staley, MD, MPH

Latest:

Managing Obesity in Survivors of Gynecologic Cancer

With nearly 40% of the adult population in the Unites States classified as obese, gynecologic oncologists must be ready to address the specific needs and considerations for this population, including for patients who have entered survivorship.